{
  "docId": "019de071-eb84-776b-8e7d-ce40a476afec",
  "docSlug": "ee62a94395a2a2b10c5eb93465b3bf02",
  "documentTitle": "Kymera | Investor Day Presentation Deck | 105 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 82,
  "pageCount": 105,
  "prevPage": 81,
  "nextPage": 83,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The left chart is a waterfall plot showing CRISPR sensitivity scores; the right chart is a dose-response curve comparing KT-253 and DS-3032.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-eb84-776b-8e7d-ce40a476afec/82",
  "deckHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec",
  "deckJsonHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec.json",
  "deckAnchorHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec#slide-82",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.55,
        "y": 0.2
      },
      "kind": "chart",
      "text": "MDM2 Degrader Superior to SMI Across Cell Line Panel",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf75858d-cef4-4876-bccd-4b8f3fa35719",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Dependency of p53WT Cell Lines on MDM2",
      "attrs": null,
      "subkind": "waterfall",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f2f1e741-d394-4edd-961d-ce2aab9a47ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.05,
        "y": 0.8
      },
      "kind": "paragraph",
      "text": "Tumor Types: Uveal melanoma, Bile Duct, Bladder, Bone, Brain, Breast, Colon, Endometrial/Uterine, Gastric, Kidney, Liver, Lung, Ovarian, Pancreatic, Rhabdoid, Sarcoma, Leukemia, Lymphoma",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0946fde7-7294-4038-a949-6d69cdeb286a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.55,
        "y": 0.8
      },
      "kind": "paragraph",
      "text": "p53WT cell lines sensitive: ALL, AML, DLBCL, Uveal Melanoma. p53 mutant cell lines were not sensitive to KT-253 or DS-3032 as expected",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f0907051-5845-4861-9ec9-e43d424c9b4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "MDM2 Dependency Seen Across a Large Subset of Tumor Types\nLarge Franchise Potential in Liquid and Solid Tumors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00dc518c-6273-4917-a63f-978ad53553d7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 84,
      "from": 76,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "baf11c7b-bcf3-45f9-a0f0-de730275483d",
      "evidence": "The deck presents the limitations of current approaches and the benefits of Kymera's MDM2 degrader.",
      "position": 1,
      "objective": "To highlight the potential consequences of not adopting TPD, specifically in the context of MDM2 and p53.",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}